Cardinal Health (CAH)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$247.18-0.58%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
Intact: The reason to own it still holds.
Cardinal Health grows revenue about 11-19% yearly. EPS guidance rose from $9.4 to $10.75. Free cash flow guidance increased to $3.5 billion. The company has strong profit margins and solid cash flow.
EPS growth may slow if demand weakens. Free cash flow could fall short if costs rise. Competition or regulatory changes could pressure margins.
The price is about 6% below our fair value near $254. Analysts expect about 14% revenue growth. Our view aligns with the Street on growth but sees slightly better value.
Breaks if: EPS guidance falls below $9.4 next fiscal year
Breaks if: Free cash flow guidance falls below $3.25 billion next fiscal year
Breaks if: YoY revenue growth falls below 7% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent earnings growth and cash generation. The current thesis state is intact, backed by strong recent financial performance and management's clear priorities.
The market currently prices CAH at a premium compared to peers, reflecting expectations of continued strong performance. However, there is an expectations gap indicating that some investors may be cautious about the company's execution quality.
Fundamentals are likely to remain strong as management is on track with its priorities, including increasing EPS guidance and expanding profit in the Pharmaceutical and Specialty Solutions segment. There is a low probability of a miss, but recent trends in earnings surprises are declining.
The thesis hinges on management's ability to maintain guidance and deliver on financial targets. Additionally, the performance of sector peers and broader economic indicators, such as job reports, could significantly impact CAH's trajectory.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Yes, our read has strengthened. The company guided for 13-15% adjusted earnings growth in fiscal 2027. This implies earnings per share above the consensus estimate. Additionally, the latest earnings beat supports a positive outlook for growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, CAH appears to be in a stable position for the next 1-3 years, with strong management focus and sector support. Not investment advice.